Utilizamos cookies para comprender de qué manera utiliza nuestro sitio y para mejorar su experiencia. Esto incluye personalizar el contenido y la publicidad. Para más información, Haga clic . Si continua usando nuestro sitio, consideraremos que acepta que utilicemos cookies.
DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculosis. It provides total solutions for POC diagnostics and offers full service for developing POC products from concept through commercialization.
The Epithod 616 COVID-19 IgM/IgG Test Kit is intended for the semi-quantitative detection of IgM and IgG antibodies to SARS-CoV-2 in whole blood, serum, and plasma from humans with a fast test time of less than two minutes. The gold nanoparticle-based immunoassay test kit is designed for use on the Epithod 616 analyzer which ensures better accuracy and improved sensitivity in analyzing results, and eliminates the risk of undesirable misreading.
La prueba Epithod SARS-CoV-2 qAb, es un análisis de diagnóstico in vitro (IVD) que puede detectar anticuerpos IgM e IgG producidos después de la infección por el virus en sangre total y suero/plasma humanos, con sensibilidad y especificidad del 97% y 100%.
A team of researchers have developed a straightforward and naked-eye-sensitive nanoshell-enhanced immunoblotting technique to detect Mycobacterium tuberculosis (MTB) antigen 85B (Ag85B).
DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculosis. It provides total solutions for POC diagnostics and offers full service for developing POC products from concept through commercialization.
The Epithod 616 Hemoglobin (Hb) Test Kit is for in-vitro diagnostic (IVD) use to determine Hemoglobin (Hb) quantitatively in whole blood from a human. It provides valuable information when the abnormal hemoglobin level is detected or when the need for further investigation in laboratory and blood donation settings.
